Tensive S.r.l. raised €14 million (US$14.5 million) in a series A financing round for its bio-absorbable breast implant Regenera, for patients undergoing reconstructive surgery after lumpectomy. The funds will be used to complete a pivotal clinical trial to evaluate the safety and performance of the technology.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Primelink Biotherapeutics (Shenzhen) Co. Ltd. has synthesized stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.
Multiple molecular pathways play a role in gastric cancer development, influencing how genetic and environmental factors interact to drive tumor growth and progressiA recent study by researchers at King Khalid University investigated a single-agent approach to simultaneously inhibit Akt and MEK1 pathways instead of using two different small molecules, which could potentially lead to increased toxicity.
Although CAR T-cell treatment can lead to clinical remissions in patients with hematological malignancies, relapse rates ultimately remain high. Previous research has found that T memory stem cell content in the infused CAR T-cell products correlated with better expansion and persistence in lymphoma patients. As a result of these observations, several approaches are being investigated to generate CAR T cells characterized by a less differentiated phenotype.
Ypsilon Therapeutics has been awarded $2.7 million in seed funding from Cancer Prevention & Research Institute of Texas (CPRIT). The award will allow Ypsilon to advance its lead therapeutic program, a next-generation T-cell receptor mimic (TCRm) antibody, to drug candidate nomination, with the aim of developing treatments for patients with solid tumors, such as triple-negative breast cancer, non-small-cell lung cancer and gastric cancer.
Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), is still one of the most lethal cancers and does not yet have an effective therapy. There is an urgent need to identify therapeutic targets to improve therapies in PDAC. Now, researchers in France have published data regarding the nucleolin antagonist N6L in combination with paclitaxel as a promising therapeutic avenue for treating PDAC.
Understanding the mechanisms of resistance to cancer treatments is necessary to find effective therapies at different stages of the disease. Scientists at UT Southwestern Medical Center studied the most frequent mutation in pancreatic ductal adenocarcinoma (PDAC), identified an escape route to a therapy in clinical trials, blocked it with another experimental compound and reduced tumors in mice.
RSS
